Publications

Plasma biomarkers identify older adults at risk of Alzheimer’s disease and related dementias in a real-world population-based cohort

Pamela C. L. Ferreira, Yingjin Zhang, Beth Snitz, Chung-Chou H. Chang, Bruna Bellaver, Erin Jacobsen, M. Ilyas Kamboh, Henrik Zetterberg, Kaj Blennow, Tharick A. Pascoal, Victor L. Villemagne, Mary Ganguli, Thomas K. Karikari.

Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association. https://doi.org/10.1002/alz.12986

Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer’s disease pathophysiology in cognitively unimpaired older adults.

Leffa DT, Ferrari-Souza JP, Bellaver B, Tissot C, Ferreira PCL, Brum WS, Caye A, Lord J, Proitsi P, Martins-Silva T, Tovo-Rodrigues L, Tudorascu DL, Villemagne VL, Cohen AD, Lopez OL, Klunk WE, Karikari TK, Rosa-Neto P, Zimmer ER, Molina BSG, Rohde LA, Pascoal TA; Alzheimer’s Disease Neuroimaging Initiative.

Mol Psychiatry. 2022 Dec 8. doi: 10.1038/s41380-022-01867-2. Online ahead of print.

Endocannabinoid System Biomarkers in Alzheimer’s Disease.

Ferreira PCL, Bellaver B, Povala G, Brum WS, Tissot C, Badji A, Sloan ME, Benedet AL, Rosa-Neto P, Ashton NJ, Pascoal TA, Leuzy A, Zimmer ER.

Cannabis Cannabinoid Res. 2022 Nov 17. doi: 10.1089/can.2022.0151. Online ahead of print.

The association of age-related and off-target retention with longitudinal quantification of [18F]MK6240 tau-PET in target regions.

Tissot C, Servaes S, Lussier FZ, Ferrari-Souza JP, Therriault J, Ferreira PCL, Bezgin G, Bellaver B, Teixeira Leffa D, Mathotaarachchi SS, Chamoun M, Stevenson J, Rahmouni N, Kang MS, Pallen V, Poltronetti NM, Wang YT, Fernandez-Arias J, Benedet AL, Zimmer ER, Soucy JP, Tudorascu DL, Cohen AD, Sharp M, Gauthier S, Massarweh G, Lopresti BJ, Klunk WE, Baker SL, Villemagne VL, Rosa-Neto P, Pascoal TA.

J Nucl Med. 2022 Nov 17:jnumed.122.264434. doi: 10.2967/jnumed.122.264434. Online ahead of print.

Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease.

Pascoal TA, Chamoun M, Lax E, Wey HY, Shin M, Ng KP, Kang MS, Mathotaarachchi S, Benedet AL, Therriault J, Lussier FZ, Schroeder FA, DuBois JM, Hightower BG, Gilbert TM, Zürcher NR, Wang C, Hopewell R, Chakravarty M, Savard M, Thomas E, Mohaddes S, Farzin S, Salaciak A, Tullo S, Cuello AC, Soucy JP, Massarweh G, Hwang H, Kobayashi E, Hyman BT, Dickerson BC, Guiot MC, Szyf M, Gauthier S, Hooker JM, Rosa-Neto P.

Nat Commun. 2022 Oct 3;13(1):5833. doi: 10.1038/s41467-022-33668-0.